|
1
|
Travis WD, Brambilla E, Burke AP, Marx A
and Nicholson AG: Introduction to The 2015 World Health
Organization Classification of Tumors of the Lung, Pleura, Thymus,
and Heart. J Thorac Oncol. 10:1240–1242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Inamura K, Satoh Y, Okumura S, Nakagawa K,
Tsuchiya E, Fukayama M and Ishikawa Y: Pulmonary adenocarcinomas
with enteric differentiation: Histologic and immunohistochemical
characteristics compared with metastatic colorectal cancers and
usual pulmonary adenocarcinomas. Am J Surg Pathol. 29:660–665.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Montezuma D, Azevedo R, Lopes P, Vieira R,
Cunha AL and Henrique R: A panel of four immunohistochemical
markers (CK7, CK20, TTF-1, and p63) allows accurate diagnosis of
primary and metastatic lung carcinoma on biopsy specimens. Virchows
Arch. 463:749–754. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Travis WD and Rekhtman N: Pathological
diagnosis and classification of lung cancer in small biopsies and
cytology: Strategic management of tissue for molecular testing.
Semin Respir Crit Care Med. 32:22–31. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fassi E, Mandruzzato M, Zamparini M,
Bianchi S, Petrelli F, Baggi A, Alberti A, Grisanti S and Berruti
A: Clinical presentation and outcome of patients with enteric-type
adenocarcinoma of the lung: A pooled analysis of published cases.
Lung Cancer. 179:1071762023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maeda R, Isowa N, Onuma H and Miura H:
Pulmonary intestinal-type adenocarcinoma. Interact Cardiovasc
Thorac Surg. 7:349–351. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yin JJ, Pollock CB and Kelly K: Mechanisms
of cancer metastasis to the bone. Cell Res. 15:57–62. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Serfaty A and Samim M: Bone tumors:
Imaging features of the most common primary osseous malignancies.
Radiol Clin North Am. 60:221–238. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger K, Yatabe Y, Powell CA, Beer D, Riely G,
Garg K, et al: International Association for the Study of Lung
Cancer/American Thoracic Society/European Respiratory Society:
International multidisciplinary classification of lung
adenocarcinoma: Executive summary. Proc Am Thorac Soc. 8:381–385.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun WW, Xu ZH, Wang CF, Wu F, Cao JM, Cui
PJ, Huang W, Jin XL, Li B, Chen KM, et al: Pulmonary enteric
adenocarcinoma with pancreatic metastasis: A case report. Oncol
Lett. 13:4651–4656. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gong J, Fan Y and Lu H: Pulmonary enteric
adenocarcinoma. Transl Oncol. 14:1011232021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ricciuti B, Alessi JV, Elkrief A, Wang X,
Cortellini A, Li YY, Vaz VR, Gupta H, Pecci F, Barrichello A, et
al: Dissecting the clinicopathologic, genomic, and immunophenotypic
correlates of KRASG12D-mutated non-small-cell lung
cancer. Ann Oncol. 33:1029–1040. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu H, Li L, Liu D and Li WM: Expression of
TTF-1, NapsinA, P63, CK5/6 in lung cancer and its diagnostic values
for histological classification. Sichuan Da Xue Xue Bao Yi Xue Ban.
48:336–341. 2017.(In Chinese). PubMed/NCBI
|
|
14
|
Sharma T, Das P, Panigrahi R, Rao CM and
Rath J: Immunocytochemical evaluation of TTF-1, Napsin-A, and p-63
for Subtyping of non-small cell lung carcinoma and
clinicopathological correlation. J Cytol. 39:180–187. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shin JH, Bae JH, Lee A, Jung CK, Yim HW,
Park JS and Lee KY: CK7, CK20, CDX2 and MUC2 Immunohistochemical
staining used to distinguish metastatic colorectal carcinoma
involving ovary from primary ovarian mucinous adenocarcinoma. Jpn J
Clin Oncol. 40:208–213. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Haraldsson S, Klarskov L, Nilbert M,
Bernstein I, Bonde J and Holck S: Differential expression of CK20,
β-catenin, and MUC2/5AC/6 in Lynch syndrome and familial colorectal
cancer type X. BMC Clin Pathol. 17:112017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lin D, Zhao Y, Li H and Xing X: Pulmonary
enteric adenocarcinoma with villin brush border immunoreactivity: A
case report and literature review. J Thorac Dis. 5:E17–E20.
2013.PubMed/NCBI
|
|
18
|
László T, Lacza A, Tóth D, Molnár TF and
Kálmán E: Pulmonary enteric adenocarcinoma indistinguishable
morphologically and immunohistologically from metastatic colorectal
carcinoma. Histopathology. 65:283–287. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu X, Chen D, Wu X and Wang Q: A pulmonary
enteric adenocarcinoma patient harboring a rare EGFR exon 19 P753S
mutation: Case report and review. Front Oncol. 12:9886252022.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao L, Huang S, Liu J, Zhao J, Li Q and
Wang HQ: Clinicopathological, radiographic, and oncogenic features
of primary pulmonary enteric adenocarcinoma in comparison with
invasive adenocarcinoma in resection specimens. Medicine
(Baltimore). 96:e81532017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li H and Cao W: Pulmonary enteric
adenocarcinoma: A literature review. J Thorac Dis. 12:3217–3226.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Q, Zhang L, Li H, Liu L, Sun X and
Liu H: Clinical features and prognosis of pulmonary enteric
adenocarcinoma: A retrospective study in China and the SEER
database. Front Oncol. 13:10991172023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Okada F, Takeda M, Fujii T, Uchiyama T,
Sasaki S, Matsuoka M, Nitta Y, Terada C, Maebo K, Morita K, et al:
Clinicopathological and genetic analyses of pulmonary enteric
adenocarcinoma. J Clin Pathol. Dec 1–2022.(Epub ahead of print).
View Article : Google Scholar
|
|
24
|
Zuo Y, Bai H, Ying JM and Wang J: Progress
in pulmonary enteric adenocarcinoma. Zhonghua Zhong Liu Za Zhi.
44:321–325. 2022.(In Chinese). PubMed/NCBI
|
|
25
|
Gu L, Wang XZ, Wen W, Lin J, Chen XF, Lai
GX, Chen L, Ouyang XJ, Zhang L, Ye J, et al: Clinical analysis of
23 patients pathologically diagnosed with primary and secondary
pulmonary enteric adenocarcinoma. Chin Med J (Engl). 132:1368–1369.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nottegar A, Tabbò F, Luchini C, Brunelli
M, Bria E, Veronese N, Santo A, Cingarlini S, Gilioli E, Ogliosi C,
et al: Pulmonary adenocarcinoma with enteric differentiation:
Immunohistochemistry and molecular morphology. Appl Immunohistochem
Mol Morphol. 26:383–387. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xie M, Chen D, Li Y, Liu X, Kuang D and Li
X: Genetic mutation profiles and immune microenvironment analysis
of pulmonary enteric adenocarcinoma. Diagn Pathol. 17:302022.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Smith G, Bounds R, Wolf H, Steele RJ,
Carey FA and Wolf CR: Activating K-Ras mutations outwith ‘hotspot’
codons in sporadic colorectal tumours-implications for personalised
cancer medicine. Br J Cancer. 102:693–703. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dong ZY, Zhong WZ, Zhang XC, Su J, Xie Z,
Liu SY, Tu HY, Chen HJ, Sun YL, Zhou Q, et al: Potential predictive
value of TP53 and KRAS mutation status for response to PD-1
blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res.
23:3012–3024. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jeanson A, Tomasini P, Souquet-Bressand M,
Brandone N, Boucekine M, Grangeon M, Chaleat S, Khobta N, Milia J,
Mhanna L, et al: Efficacy of immune checkpoint inhibitors in
KRAS-Mutant non-small cell lung cancer (NSCLC). J Thorac Oncol.
14:1095–1101. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhou C, Wang Y, Zhao J, Chen G, Liu Z, Gu
K, Huang M, He J, Chen J, Ma Z, et al: Efficacy and biomarker
analysis of camrelizumab in combination with apatinib in patients
with advanced nonsquamous NSCLC previously treated with
chemotherapy. Clin Cancer Res. 27:1296–1304. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jaramillo MC and Zhang DD: The emerging
role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev.
27:2179–2191. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Menegon S, Columbano A and Giordano S: The
dual roles of NRF2 in cancer. Trends Mol Med. 22:578–593. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Marinelli D, Mazzotta M, Scalera S,
Terrenato I, Sperati F, D'Ambrosio L, Pallocca M, Corleone G,
Krasniqi E, Pizzuti L, et al: KEAP1-driven co-mutations in lung
adenocarcinoma unresponsive to immunotherapy despite high tumor
mutational Burden. Ann Oncol. 31:1746–1754. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ricciuti B, Arbour KC, Lin JJ, Vajdi A,
Vokes N, Hong L, Zhang J, Tolstorukov MY, Li YY, Spurr LF, et al:
Diminished efficacy of programmed death-(Ligand)1 inhibition in
STK11- and KEAP1-Mutant lung adenocarcinoma is affected by KRAS
mutation status. J Thorac Oncol. 17:399–410. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cresto N, Forner-Piquer I, Baig A,
Chatterjee M, Perroy J, Goracci J and Marchi N: Pesticides at brain
borders: Impact on the blood-brain barrier, neuroinflammation, and
neurological risk trajectories. Chemosphere. 324:1382512023.
View Article : Google Scholar : PubMed/NCBI
|
